1
|
Wang T, Pang L, He M, Wang Z. Small-molecule inhibitors targeting apoptosis signal-regulated kinase 1. Eur J Med Chem 2023; 262:115889. [PMID: 37883895 DOI: 10.1016/j.ejmech.2023.115889] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2023] [Revised: 10/17/2023] [Accepted: 10/18/2023] [Indexed: 10/28/2023]
Abstract
Apoptosis signal regulated kinase 1 (ASK1, also known as MAP3K5) is a member of the mitogen activated protein kinase kinase kinase (MAP3K) family. Since its first isolation from a human macrophage library in 1996, its research has been ongoing for over 25 years. A large number of reports have revealed that ASK1, as a key activator of the p38 mitogen-activated protein kinase and c-Jun N-terminal kinase (JNK) signaling cascade, responds to various stressors, and its inhibitors have important potential value in the treatment of diseases such as inflammation, cancer, and the nervous system and so on. This review summarizes the recent development in this field, including the structure and signaling pathways of ASK1, with a particular focus on the structure-activity relationships, and the hit-to-lead optimization strategies.
Collapse
Affiliation(s)
- Tiantian Wang
- College of Pharmacy, Jiangxi University of Chinese Medicine, Nanchang, 330004, PR China; National Pharmaceutical Engineering Center for Solid Preparation in Chinese Herbal Medicine, Jiangxi University of Chinese Medicine, Nanchang, 330006, PR China
| | - Lidan Pang
- College of Pharmacy, Jiangxi University of Chinese Medicine, Nanchang, 330004, PR China
| | - Mengni He
- College of Pharmacy, Jiangxi University of Chinese Medicine, Nanchang, 330004, PR China
| | - Zengtao Wang
- College of Pharmacy, Jiangxi University of Chinese Medicine, Nanchang, 330004, PR China.
| |
Collapse
|
2
|
Wang Y, Hou S, Tong Y, Li H, Hua Y, Fan Y, Chen X, Yang Y, Liu H, Lu T, Chen Y, Zhang Y. Discovery of potent apoptosis signal-regulating kinase 1 inhibitors via integrated computational strategy and biological evaluation. J Biomol Struct Dyn 2019; 38:4385-4396. [PMID: 31612792 DOI: 10.1080/07391102.2019.1680439] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Apoptosis signal-regulating Kinase 1 (ASK1) has been confirmed as a potential therapeutic target for the treatment of non-alcoholic steatohepatitis (NASH) disorder and the discovery of ASK1 inhibitors has attracted increasing attention. In this work, a series of in silico methods including pharmacophore screening, docking binding site analysis, protein-ligand interaction fingerprint (PLIF) similarity investigation and molecular docking were applied to find the potential hits from commercial compound databases. Five compounds with potential inhibitory activity were purchased and submitted to biological activity validation. Thus, one hit compound was discovered with micromolar IC50 value (10.59 μM) against ASK1. Results demonstrated that the integration of computation methods and biological test was quite reliable for the discovery of potent ASK1 inhibitors and the strategy could be extended to other similar targets of interest.
Collapse
Affiliation(s)
- Yuchen Wang
- School of Science, China Pharmaceutical University, Nanjing, Jiangsu, China
| | - Shaohua Hou
- School of Science, China Pharmaceutical University, Nanjing, Jiangsu, China
| | - Yu Tong
- School of Science, China Pharmaceutical University, Nanjing, Jiangsu, China
| | - Hongmei Li
- School of Science, China Pharmaceutical University, Nanjing, Jiangsu, China
| | - Yi Hua
- School of Science, China Pharmaceutical University, Nanjing, Jiangsu, China
| | - Yuanrong Fan
- School of Science, China Pharmaceutical University, Nanjing, Jiangsu, China
| | - Xingye Chen
- School of Science, China Pharmaceutical University, Nanjing, Jiangsu, China
| | - Yan Yang
- School of Science, China Pharmaceutical University, Nanjing, Jiangsu, China
| | - Haichun Liu
- School of Science, China Pharmaceutical University, Nanjing, Jiangsu, China
| | - Tao Lu
- State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, Jiangsu, China
| | - Yadong Chen
- School of Science, China Pharmaceutical University, Nanjing, Jiangsu, China
| | - Yanmin Zhang
- School of Science, China Pharmaceutical University, Nanjing, Jiangsu, China
| |
Collapse
|
3
|
da Silva Costa J, da Silva Lopes Costa K, Cruz JV, da Silva Ramos R, Silva LB, Do Socorro Barros Brasil D, de Paula da Silva CHT, Dos Santos CBR, da Cruz Macedo WJ. Virtual Screening and Statistical Analysis in the Design of New Caffeine Analogues Molecules with Potential Epithelial Anticancer Activity. Curr Pharm Des 2019; 24:576-594. [PMID: 28699538 PMCID: PMC5944109 DOI: 10.2174/1381612823666170711112510] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2017] [Revised: 06/20/2017] [Accepted: 06/30/2017] [Indexed: 12/21/2022]
Abstract
About 132 thousand cases of melanoma (more severe type of skin cancer) were registered in 2014 according to the World Health Organization. This type of cancer significantly affects the quality of life of individuals. Caffeine has shown potential inhibitory effect against epithelial cancer. In this study, it was proposed to obtain new caffeine-based molecules with potential epithelial anticancer activity. For this, a training set of 21 molecules was used for pharmacophore perception procedures. Multiple linear regression analyses were used to propose mono-, bi-, tri-, and tetra-parametric models applied in the prediction of the activity. The generated pharmacophore was used to select 350 molecules available at the ZINCpharmer server, followed by reduction to 24 molecules, after selection using the Tanimoto index, yielding 10 molecules after final selection by predicted activity values > 1.5229. These ten mole-cules had better pharmacokinetic properties than the other ones used as reference and within the clinical-ly significant limits. Only two molecules show minor hits of toxicity and were submitted to molecular docking procedures, showing BFE (binding free energy) values lower than the reference values. Statisti-cal analyses indicated strong negative correlations between BFE and pharmacophoric properties (high influence on BFE lowering) and practically null correlation between BFE and BBB. The two most prom-ising molecules can be indicated as candidates for further in vitro and in vivo analyzes.
Collapse
Affiliation(s)
- Josivan da Silva Costa
- Postgraduate Program in Biotechnology and Biodiversity-Network BIONORTE, Federal University of the Para, Belem, Brazil.,Laboratory of Modeling and Computational Chemistry, Federal University of Amapa, Department of Biological Sciences. Rod. Juscelino Kubitschek, Km 02, s/n, Jardim Marco Zero, 68902-280 Macapa-AP, Brazil.,Institute of Technology, Federal University of Para, Av. Augusto Correa, 01, Belem, Para 66075-900, Brazil
| | - Karina da Silva Lopes Costa
- Laboratory of Modeling and Computational Chemistry, Federal University of Amapa, Department of Biological Sciences. Rod. Juscelino Kubitschek, Km 02, s/n, Jardim Marco Zero, 68902-280 Macapa-AP, Brazil
| | - Josiane Viana Cruz
- Laboratory of Modeling and Computational Chemistry, Federal University of Amapa, Department of Biological Sciences. Rod. Juscelino Kubitschek, Km 02, s/n, Jardim Marco Zero, 68902-280 Macapa-AP, Brazil
| | - Ryan da Silva Ramos
- Laboratory of Modeling and Computational Chemistry, Federal University of Amapa, Department of Biological Sciences. Rod. Juscelino Kubitschek, Km 02, s/n, Jardim Marco Zero, 68902-280 Macapa-AP, Brazil
| | - Luciane Barros Silva
- Laboratory of Modeling and Computational Chemistry, Federal University of Amapa, Department of Biological Sciences. Rod. Juscelino Kubitschek, Km 02, s/n, Jardim Marco Zero, 68902-280 Macapa-AP, Brazil
| | | | - Carlos Henrique Tomich de Paula da Silva
- Computational Laboratory of Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, Sao Paulo, Brazil
| | - Cleydson Breno Rodrigues Dos Santos
- Laboratory of Modeling and Computational Chemistry, Federal University of Amapa, Department of Biological Sciences. Rod. Juscelino Kubitschek, Km 02, s/n, Jardim Marco Zero, 68902-280 Macapa-AP, Brazil
| | - Williams Jorge da Cruz Macedo
- Laboratory of Molecular Modeling and Simulation System, Federal Rural University of Amazonia, Rua Joao Pessoa, 121, Campus Capanema-Centro, Capanema, Para 68700-030, Brazil
| |
Collapse
|
5
|
Lanier M, Pickens J, Bigi SV, Bradshaw-Pierce EL, Chambers A, Cheruvallath ZS, Cole D, Dougan DR, Ermolieff J, Gibson T, Halkowycz P, Hirokawa A, Ivetac A, Miura J, Nunez E, Sabat M, Tyhonas J, Wang H, Wang X, Swann S. Structure-Based Design of ASK1 Inhibitors as Potential Agents for Heart Failure. ACS Med Chem Lett 2017; 8:316-320. [PMID: 28337323 DOI: 10.1021/acsmedchemlett.6b00481] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2016] [Accepted: 02/08/2017] [Indexed: 11/28/2022] Open
Abstract
Apoptosis signal-regulating kinase 1 (ASK1/MAP3K) is a mitogen-activated protein kinase family member shown to contribute to acute ischemia/reperfusion injury. Using structure-based drug design, deconstruction, and reoptimization of a known ASK1 inhibitor, a lead compound was identified. This compound displayed robust MAP3K pathway inhibition and reduction of infarct size in an isolated perfused heart model of cardiac injury.
Collapse
Affiliation(s)
- Marion Lanier
- Departments of Medicinal Chemistry, ‡Drug Metabolism Pharmacokinetics, §Structural Biology, and ∥Discovery Biology, Gastrointestinal Drug Discovery Unit, Takeda Pharmaceuticals, 10410 Science Center Drive, San Diego, California 92121, United States
| | - Jason Pickens
- Departments of Medicinal Chemistry, ‡Drug Metabolism Pharmacokinetics, §Structural Biology, and ∥Discovery Biology, Gastrointestinal Drug Discovery Unit, Takeda Pharmaceuticals, 10410 Science Center Drive, San Diego, California 92121, United States
| | - Simone V. Bigi
- Departments of Medicinal Chemistry, ‡Drug Metabolism Pharmacokinetics, §Structural Biology, and ∥Discovery Biology, Gastrointestinal Drug Discovery Unit, Takeda Pharmaceuticals, 10410 Science Center Drive, San Diego, California 92121, United States
| | - Erica L. Bradshaw-Pierce
- Departments of Medicinal Chemistry, ‡Drug Metabolism Pharmacokinetics, §Structural Biology, and ∥Discovery Biology, Gastrointestinal Drug Discovery Unit, Takeda Pharmaceuticals, 10410 Science Center Drive, San Diego, California 92121, United States
| | - Alison Chambers
- Departments of Medicinal Chemistry, ‡Drug Metabolism Pharmacokinetics, §Structural Biology, and ∥Discovery Biology, Gastrointestinal Drug Discovery Unit, Takeda Pharmaceuticals, 10410 Science Center Drive, San Diego, California 92121, United States
| | - Zacharia S. Cheruvallath
- Departments of Medicinal Chemistry, ‡Drug Metabolism Pharmacokinetics, §Structural Biology, and ∥Discovery Biology, Gastrointestinal Drug Discovery Unit, Takeda Pharmaceuticals, 10410 Science Center Drive, San Diego, California 92121, United States
| | - Derek Cole
- Departments of Medicinal Chemistry, ‡Drug Metabolism Pharmacokinetics, §Structural Biology, and ∥Discovery Biology, Gastrointestinal Drug Discovery Unit, Takeda Pharmaceuticals, 10410 Science Center Drive, San Diego, California 92121, United States
| | - Douglas R. Dougan
- Departments of Medicinal Chemistry, ‡Drug Metabolism Pharmacokinetics, §Structural Biology, and ∥Discovery Biology, Gastrointestinal Drug Discovery Unit, Takeda Pharmaceuticals, 10410 Science Center Drive, San Diego, California 92121, United States
| | - Jacques Ermolieff
- Departments of Medicinal Chemistry, ‡Drug Metabolism Pharmacokinetics, §Structural Biology, and ∥Discovery Biology, Gastrointestinal Drug Discovery Unit, Takeda Pharmaceuticals, 10410 Science Center Drive, San Diego, California 92121, United States
| | - Tony Gibson
- Departments of Medicinal Chemistry, ‡Drug Metabolism Pharmacokinetics, §Structural Biology, and ∥Discovery Biology, Gastrointestinal Drug Discovery Unit, Takeda Pharmaceuticals, 10410 Science Center Drive, San Diego, California 92121, United States
| | - Petro Halkowycz
- Departments of Medicinal Chemistry, ‡Drug Metabolism Pharmacokinetics, §Structural Biology, and ∥Discovery Biology, Gastrointestinal Drug Discovery Unit, Takeda Pharmaceuticals, 10410 Science Center Drive, San Diego, California 92121, United States
| | - Aki Hirokawa
- Departments of Medicinal Chemistry, ‡Drug Metabolism Pharmacokinetics, §Structural Biology, and ∥Discovery Biology, Gastrointestinal Drug Discovery Unit, Takeda Pharmaceuticals, 10410 Science Center Drive, San Diego, California 92121, United States
| | - Anthony Ivetac
- Departments of Medicinal Chemistry, ‡Drug Metabolism Pharmacokinetics, §Structural Biology, and ∥Discovery Biology, Gastrointestinal Drug Discovery Unit, Takeda Pharmaceuticals, 10410 Science Center Drive, San Diego, California 92121, United States
| | - Joanne Miura
- Departments of Medicinal Chemistry, ‡Drug Metabolism Pharmacokinetics, §Structural Biology, and ∥Discovery Biology, Gastrointestinal Drug Discovery Unit, Takeda Pharmaceuticals, 10410 Science Center Drive, San Diego, California 92121, United States
| | - Evan Nunez
- Departments of Medicinal Chemistry, ‡Drug Metabolism Pharmacokinetics, §Structural Biology, and ∥Discovery Biology, Gastrointestinal Drug Discovery Unit, Takeda Pharmaceuticals, 10410 Science Center Drive, San Diego, California 92121, United States
| | - Mark Sabat
- Departments of Medicinal Chemistry, ‡Drug Metabolism Pharmacokinetics, §Structural Biology, and ∥Discovery Biology, Gastrointestinal Drug Discovery Unit, Takeda Pharmaceuticals, 10410 Science Center Drive, San Diego, California 92121, United States
| | - John Tyhonas
- Departments of Medicinal Chemistry, ‡Drug Metabolism Pharmacokinetics, §Structural Biology, and ∥Discovery Biology, Gastrointestinal Drug Discovery Unit, Takeda Pharmaceuticals, 10410 Science Center Drive, San Diego, California 92121, United States
| | - Haixia Wang
- Departments of Medicinal Chemistry, ‡Drug Metabolism Pharmacokinetics, §Structural Biology, and ∥Discovery Biology, Gastrointestinal Drug Discovery Unit, Takeda Pharmaceuticals, 10410 Science Center Drive, San Diego, California 92121, United States
| | - Xiaolun Wang
- Departments of Medicinal Chemistry, ‡Drug Metabolism Pharmacokinetics, §Structural Biology, and ∥Discovery Biology, Gastrointestinal Drug Discovery Unit, Takeda Pharmaceuticals, 10410 Science Center Drive, San Diego, California 92121, United States
| | - Steve Swann
- Departments of Medicinal Chemistry, ‡Drug Metabolism Pharmacokinetics, §Structural Biology, and ∥Discovery Biology, Gastrointestinal Drug Discovery Unit, Takeda Pharmaceuticals, 10410 Science Center Drive, San Diego, California 92121, United States
| |
Collapse
|